Overview of Dextrose 50% Injection

Property	Description
Active ingredient	Dextrose (D-Glucose)
Form	Solution for intravenous injection
Pharmacological class	Caloric agent, Fluid and nutrient replenisher
General purpose	Provides immediate energy and fluid support
Origin	Derived monosaccharide (carbohydrate)

What Type of Medicine is Dextrose 50% Injection?

Dextrose 50% Injection is a sterile, high-concentration solution of the simple sugar Dextrose (D-Glucose) prepared for rapid intravenous administration. It is officially classified as a caloric agent and a fluid and nutrient replenisher, serving as a critical source of immediate, highly accessible energy for the body. The active ingredient, Dextrose Monohydrate, is a chemically pure and water-soluble form of D-Glucose, which is the same monosaccharide sugar naturally found and metabolized by the human body.

This medicine belongs to the pharmacological class of caloric agents because its primary role is providing calories, and it is identified as a hypertonic solution due to its high concentration of sugar. Unlike standard intravenous fluids (like Dextrose 5% solutions), the 50% concentration is significantly more concentrated than blood plasma, differentiating it as a high-potency metabolic intervention. This specific formulation is widely clinically recognized for its capacity to address urgent metabolic needs in controlled settings.

Composition and Purpose of the 50% Glucose Solution

The composition is straightforward: Dextrose Monohydrate is dissolved in a base of Sterile Water for Injection to create the final 50% concentration solution. This specific high-strength formulation allows clinicians to deliver a large amount of glucose and associated calories efficiently and in a minimum volume of fluid. The high-concentration and intravenous route differentiate this preparation, making it the standard choice for situations requiring a rapid, substantial caloric boost.

The general purpose is to act as an indispensable, immediate-availability energy source and aid in fluid replenishment. By quickly restoring the body's essential fuel supply, it supports vital functions and helps resolve acute metabolic deficits that require a substantial, rapid boost of readily available carbohydrates.

Regulatory References

What side effects are possible with Dextrose 50% Injection?

Possible Side Effects and Safety Information

The safety profile for Dextrose 50% Injection is documented by regulatory authorities and primarily focuses on reactions related to its high concentration and metabolic impact. Adverse reactions are grouped by system and frequency.

Adverse Reactions Classified by System

The most common documented adverse reactions are related to Metabolism and Nutrition Disorders, including hyperglycemia (high blood sugar), hyponatremia (low blood sodium), and general electrolyte imbalance. The other primary category involves General Disorders and Administration Site Conditions, which includes phlebitis, vein thrombosis, and infection at the injection site, due to the hypertonic nature of the solution.

Serious Adverse Reactions

Official labeling documents serious adverse reactions. These include the risk of a hyperosmolar hyperglycemic state and severe, systemic hypersensitivity reactions, such as anaphylaxis. A specific, serious neurological complication documented is acute hyponatremic encephalopathy, which results from severely low sodium levels.

Population-Specific and Temporal Safety Considerations

Special population safety statements exist for specific groups. Low birth weight infants have an increased documented risk of severe complications, including intracerebral hemorrhage. Caution is also specified for older adults and individuals with impaired renal function. Regarding temporal patterns, the official label notes that rebound hypoglycemia is a possible adverse event upon abrupt discontinuation of the infusion. The medication is contraindicated in patients with known hypersensitivity to dextrose or corn products, clinically significant hyperglycemia, or certain types of intracranial hemorrhage.

Overdose and Emergency Response

Dextrose 50% Injection Overdose and When to Seek Help

Overdose or too-rapid administration of Dextrose 50% Injection may result in acute fluid and solute overloading, leading to severe metabolic imbalance. The official regulatory profile focuses on the consequences of excessive glucose and fluid load.

Manifestations and Outcomes	Regulator-Documented Findings
Documented Presentations	Severe hyperglycemia, glycosuria, overhydration, congested states, and electrolyte imbalances (including hyponatremia and hypokalemia).
Severe Outcomes	Hyperosmolar coma, pulmonary edema, and acute hyponatremic encephalopathy (which may involve seizures or loss of consciousness).
Emergency Action	The infusion must be discontinued immediately and appropriate therapeutic countermeasures must be instituted.

Management and Specific Considerations

The required management is supportive, focusing on the correction of fluid and electrolyte imbalances and insulin administration as needed for hyperglycemia. Immediate medical help is required for any sign of the documented severe outcomes. Official labeling notes that Very Low Birth Weight Infants are at specific risk for increased serum osmolality and possible intracerebral hemorrhage. Elderly patients are also noted to have an increased risk of toxic reactions due to potential decreased renal function.

Therapeutic Uses of Dextrose 50% Injection

What Dextrose 50% Injection Treats: Main Uses and Benefits

Dextrose 50% Injection is a medication used in clinical settings that involve acute or unstable symptom patterns to address metabolic and symptomatic imbalances. Its main clinical use is in addressing conditions associated with acute or disruptive episodes, specifically hypoglycemia (very low blood sugar) induced by insulin.

This solution is generally applied in scenarios where additional management of discomfort is required, often when symptoms related to heightened physiological activity, such as confusion, loss of consciousness, or seizures, occur in situations where patients experience severe physiological stress. This medication supports the body during these episodes, and helps maintain a sense of stability when symptoms are more noticeable, contributing to easing the overall symptom burden. It is commonly used to help with symptoms that create noticeable physiological strain, and may also be part of supportive nutritional assistance. It is commonly used across conditions presenting with systemic or localized discomfort.

“It may provide supportive relief when symptoms interfere with routine activities.”

Quick Fact: May help with Symptoms that Interfere with Daily Functioning

Regulatory References

Dextrose Injection prescribing information

Eligibility and Restrictions for Use

Who can and cannot use Dextrose 50% Injection?

Eligibility for Dextrose 50% Injection is strictly defined by regulatory documentation, focusing on the patient’s existing metabolic state and physiological fluid status.

Absolute Contraindications

This medicine must not be used in populations with clinically significant hyperglycemia (high blood sugar) or a known hypersensitivity to dextrose or corn products. It is also contraindicated for patients with intracranial or intraspinal hemorrhage, severe dehydration, hepatic coma, or delirium tremens when associated with dehydration.

Restricted and Conditional Use

Use is permitted across adult, pediatric, and older adult populations but requires specific caution in several groups. Patients with impaired glucose tolerance (such as diabetes mellitus), thiamine deficiency, severe malnutrition (due to refeeding syndrome risk), or pre-existing renal or heart disease (due to fluid overload risk) must be closely monitored. Use in children and neonates requires heightened caution due to an increased risk of fluid and glucose imbalances.

Pregnancy and Lactation

Dextrose 50% is classified as Pregnancy Category C, meaning it should be used only if clearly needed. Caution is also advised during lactation and when administered during labor (due to hyponatremia risk).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Dextrose 50% Injection establishes specific rules regarding co-administration, primarily focusing on physical incompatibilities and pharmacodynamic effects, rather than classic pharmacokinetic interactions.

Administration and Physical Incompatibility Restrictions

Interacting Product/Substance	Official Restriction or Outcome
Blood Products (Whole blood, Plasma)	Must not be administered simultaneously through the same infusion set, as this is associated with pseudoagglutination or hemolysis of red blood cells.
Other Additives	Requires mandatory verification for solubility, stability, and appropriate pH range before mixing and administration to avoid physicochemical incompatibility.
Corn or Corn Products	Use is contraindicated in individuals with a known allergy to these substances, as the Dextrose is purified from corn.

Pharmacodynamic and Population-Specific Interactions

The co-administration of Dextrose 50% Injection with other products that affect glycemic control may result in counter-regulatory effects on blood glucose levels. Similarly, concurrent use with medicinal products that affect fluid and/or electrolyte balance, such as Vasopressin agonists, may compound the risk of hyponatremia and fluid disturbances.

A population-specific constraint is documented regarding Aluminum content. Patients with impaired renal function, including preterm infants, are at an increased risk of aluminum toxicity due to reduced clearance with prolonged parenteral administration of the injection.

Mechanism of Action

Dextrose, which is D-glucose, functions as a primary biological substrate for cellular metabolism. Following intravenous administration, the high concentration of D-glucose rapidly increases the circulating plasma glucose level, establishing a steep concentration gradient across the capillary endothelium and the cell membrane. This gradient drives the facilitated diffusion of D-glucose into most cells via ubiquitous glucose transporter (GLUT) proteins, such as GLUT1 and GLUT4, which serve as the primary biological targets.

Upon entry into the cytoplasm, D-glucose is rapidly phosphorylated by hexokinase to form glucose-6-phosphate. This initial step commits the molecule to the glycolytic pathway, an intracellular process where it is metabolized to pyruvate, generating a net gain of adenosine triphosphate (ATP) via substrate-level phosphorylation. Pyruvate then enters the mitochondria and is converted to acetyl-CoA for entry into the tricarboxylic acid (TCA) cycle, culminating in significant ATP production through oxidative phosphorylation. The downstream cascade is the accelerated generation of ATP, increasing the intracellular energy supply necessary for all cellular functions, particularly in obligate glucose consumers like neurons and erythrocytes.

System-level physiological modulation involves the rapid expansion of the readily available energy substrate pool, counteracting systemic energy deficit by fueling the highly demanding central nervous system and other organs.

Dosage and Administration Information

How to Use Dextrose 50% Injection: Official Administration Guidelines

The administration of Dextrose 50% Injection follows precise instructions specific to its use as a high-concentration intravenous solution. The following guidelines define the standardized procedure for proper usage.

Official Administration and Dosing

Feature	Instruction
Route of Administration	Strictly intravenous infusion. Administration must not be subcutaneous or intramuscular.
Standard Dosing Range	For adults and patients 12 years and older: The typical dose is 10 to 25 grams of dextrose, equivalent to 20 to 50 mL of the 50% solution.
Frequency and Pattern	Administered as a single, acute dose, with repeated doses permitted as clinically appropriate.
Maximum Rate of Use	The solution must be infused slowly at a rate not exceeding 0.5 grams per kilogram of body weight per hour.

Procedural and Population-Specific Rules

Administration should be performed into a central vein or a large peripheral vein due to the hypertonic nature of the solution. A specific rule applies to pediatric patients between 2 and 11 years of age, for whom administration is limited to a central vein only.

Key procedural constraints include the requirement to visually inspect the solution for clarity and container integrity before use. Furthermore, the solution must not be administered simultaneously with blood products through the same infusion set, and any unused portion of the single-dose container must be discarded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dextrose 50% Injection

The evidence landscape for Dextrose 50% Injection primarily consists of randomized controlled trials (RCTs) and observational studies that explore its use as a metabolic intervention in acute care, alongside physiological data related to its function as a caloric substrate in comprehensive nutritional support.

Evidence for Use in Acute, Symptomatic Hypoglycemia

Research on Dextrose 50% was studied for the management of acute hypoglycemia—a condition associated with acute or disruptive episodes, often resulting in altered mental status or temporary physiological imbalance. The evidence comes primarily from short-term randomized controlled trials (RCTs) and prospective observational studies conducted in acute care settings. These studies mainly involved adult patients and studies monitored outcomes related to systemic or functional imbalance.

The main outcomes that researchers measured were the time taken to measure a shift to a target serum glucose level (a biomarker outcome) and the time taken to observe changes in baseline mental status (an outcome reflecting functional measures). When Dextrose 50% was evaluated against lower-concentration Dextrose solutions, findings were mixed; some trials reported patterns of physiological change that were similar between the formulations. Long-term effects are not fully established because follow-up durations were limited.

Evidence as a Caloric and Fluid Source in Supportive Care

For its use as a source of calories and fluid, Dextrose 50% is primarily supported by post-marketing analyses and observational cohort studies where it is included as a primary component of Parenteral Nutrition (PN). Research describes the administration in patients requiring total or supplemental nutritional support. Studies monitored outcomes related to the safe and consistent delivery of caloric load, maintenance of fluid balance, and tracking of essential laboratory parameters. The evidence for this application reflects its role as a caloric substrate and its inclusion in comprehensive nutritional regimens.

What Remains Uncertain in the Research Landscape

The research base for Dextrose 50% highlights areas where data are still emerging. While the immediate physiological response in acute settings is well-documented, long-term effects are not fully established following a single intervention due to limited follow-up in the clinical trials. Comparative evidence is lacking against pharmacological alternatives, as research primarily compares it against lower-concentration Dextrose solutions. Subgroup findings are uncertain for specific patient demographics outside of the main adult cohorts.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dextrose 50% Injection (FAQ)

Q: What does it mean that Dextrose 50% Injection is a 'hypertonic' solution?

Dextrose 50% is officially defined as a hypertonic solution. This means that its concentration of sugar particles is much higher than the concentration of particles normally found in your blood plasma. This high concentration is associated with the delivery of a large, rapid amount of glucose and calories in a minimal volume.

Q: How is Dextrose 50% different from a regular saline IV bag?

Official information classifies Dextrose 50% as a caloric agent and a fluid and nutrient replenisher because its primary role is providing sugar (glucose) energy. A regular saline (sodium chloride) bag, on the other hand, is generally classified as an electrolyte solution or volume expander used primarily to restore fluid and sodium balance, not to provide substantial calories.

Q: What is extravasation and why is it a major risk with Dextrose 50%?

Regulatory documents explicitly warn that extravasation is a potential complication. Extravasation occurs when the solution leaks out of the vein into the surrounding tissue. Because Dextrose 50% is highly concentrated (hypertonic), leakage is associated with irritation and tissue damage. Therefore, official instructions specify that it is typically administered into a large or central vein.

Q: What is phlebitis and can Dextrose 50% Injection cause it?

Phlebitis is a term for inflammation or swelling of a vein. Official product labeling lists venous thrombosis or phlebitis extending from the injection site as a documented adverse reaction. This reaction is documented to be related to the irritating properties of the high-concentration solution or the site of administration.

Q: Can Dextrose 50% affect my potassium or phosphate levels?

Yes, official safety information indicates that the use of concentrated dextrose solutions may lead to electrolyte deficits. Serum potassium and phosphate levels are specifically mentioned as being affected. Official information indicates that monitoring of these levels is sometimes necessary during administration.

Q: What are the signs of hyperosmolar syndrome from Dextrose 50%?

A hyperosmolar state is a serious adverse reaction documented to be associated with the injection. Signs of this complication may include mental confusion and/or loss of consciousness. To help manage the risk of this complication, administration is often performed using controlled, slow infusion rates.

Q: Can Dextrose 50% cause fluid retention or swelling?

Regulatory documents state that the administration of this solution can lead to fluid and/or solute overloading. This may potentially result in overhydration, congested states, or pulmonary edema (fluid in the lungs). Caution is specifically advised for patients who are known to be at risk of fluid overload.

Q: Can Dextrose 50% cause high blood sugar (hyperglycemia) even if the patient wasn't hypoglycemic initially?

Yes, significant hyperglycemia (high blood sugar) is a documented adverse reaction that can result from using Dextrose 50%. This can be a documented result of the rapid administration of the solution or when the body’s glucose utilization rate is surpassed.

Q: Is there an increased risk for elderly patients using Dextrose 50%?

Official documents note that older adult patients may be at an increased risk of complications and require careful monitoring. These patients may be at an increased risk of hospital-acquired hyponatremia (low sodium levels) when receiving Dextrose 50% Injection.

Q: Is Dextrose 50% used during pregnancy or while breastfeeding?

Regulatory information classifies this medicine as Pregnancy Category C, meaning it should be given to a pregnant woman only if clearly needed. The official document also notes that caution is advised when administered to a nursing mother.

Q: Is there a concern about using Dextrose 50% in patients with alcoholism or malnutrition?

Official documents state that Dextrose 50% is contraindicated in acute alcohol withdrawal, as the product label indicates a potential to worsen symptoms in patients with thiamine deficiency. Caution is also advised for patients with severe malnutrition (due to the risk of refeeding syndrome).

Q: Can Dextrose 50% Injection be used in children or pediatric patients?

Dextrose 50% Injection is used in pediatric patients, but they are documented to be at higher risk for complications like hospital-acquired hyponatremia and fluid imbalances. Use in very low birth weight infants is documented to require specific caution due to increased risks of complications.

Q: Can Dextrose 50% cause a sudden severe headache or confusion?

Yes, the official labeling lists headache and altered mentation (changes in thinking or awareness) as potential signs of hypersensitivity reactions. Additionally, mental confusion is a listed symptom of the serious complications of a hyperosmolar state or acute hyponatremic encephalopathy.

Q: Why does the solution have an acidic pH?

The solution is documented to have an acidic pH range of 3.2 to 6.5. This low pH is an inherent property of the formulation. Regulatory documents note that sodium hydroxide and/or hydrochloric acid may be added during manufacturing for final pH adjustment.

Q: What is the difference between Dextrose 50% Injection and Dextrose 10% Injection?

Dextrose 50% is a hypertonic, high-concentration solution (500 mg/mL) intended for treating acute hypoglycemia or as a component of nutritional support. Dextrose 10% is a lower-concentration, less hypertonic solution used for different fluid and carbohydrate replacement needs.

Q: Why is Dextrose 50% not administered into a muscle or under the skin?

Regulatory documents are clear that Dextrose 50% solutions must not be administered subcutaneously (under the skin) or intramuscularly (into a muscle). The administration route is strictly intravenous (into a vein) to ensure rapid effect and to manage the risk of local tissue damage associated with the highly concentrated solution.

Q: What research evidence supports the use of Dextrose 50% for low blood sugar?

Dextrose 50% Injection is officially indicated for the treatment of insulin hypoglycemia (often called insulin shock) to rapidly restore blood glucose levels. This use is based on clinical consensus and historical data documented by regulatory bodies.

Q: What happens if Dextrose 50% is abruptly stopped after prolonged use?

Official safety warnings state that if Dextrose 50% Injection is abruptly discontinued after a prolonged period, patients may be at risk of developing rebound hypoglycemia. To help mitigate this documented risk, official guidance describes the practice of switching patients to a lower-concentration dextrose injection (such as 5% or 10%).

Q: Why is the injection site monitored so closely?

The injection site is closely monitored because adverse reactions related to administration, including infection, phlebitis (vein inflammation), venous thrombosis (blood clots), and extravasation (leakage outside the vein), are documented as possible events. This monitoring is a key procedural component in the administration guidelines.

How should Dextrose 50% Injection be stored and disposed of?

Official Storage and Disposal Requirements

Dextrose 50% Injection must be stored under specific conditions to maintain its quality and sterility. Storage is typically required at room temperature, such as 25°C (77°F), and the product must be protected from freezing and avoid excessive heat. The container should be visually inspected for leaks, damage, and clarity before use, and any solution that is cloudy, discolored, or contains particles must be discarded.

Since this is a single-dose product, any unused portion must be discarded immediately after use. Solutions containing any additives or that have been diluted must be used promptly and not stored. Final disposal of the unused medication and waste materials must strictly follow local authority requirements and regulations.

Dextrose 50% Injection